Genelux (NASDAQ:GNLX) Hits New 1-Year High at $21.96
Genelux (NASDAQ:GNLX) Hits New 1-Year High at $21.96
Genelux Co. (NASDAQ:GNLX – Get Rating) shares hit a new 52-week high during trading on Monday . The stock traded as high as $21.96 and last traded at $21.92, with a volume of 132537 shares traded. The stock had previously closed at $18.47.
Wall Street Analysts Forecast Growth
Separately, Benchmark assumed coverage on shares of Genelux in a research report on Wednesday, February 15th. They issued a "speculative buy" rating and a $10.00 target price on the stock.
Genelux Stock Down 4.7 %
About Genelux
(Get Rating)
Genelux Corporation is a clinical-stage biopharmaceutical company. It focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus.
Featured Stories
- Get a free copy of the StockNews.com research report on Genelux (GNLX)
- Occidental Petroleum: What Would Warren Buffett Do?
- Is Unity Software Earnings Fallout a Buying Opportunity?
- Why Wall Street Is Still So Constructive on Aecom Stock
- Latest Tech Layoffs at Dell May Provide Buying Opportunity
- Here's What Happens When a Stock is Removed from an Index
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
Genelux Co. (NASDAQ:GNLX – Get Rating) shares hit a new 52-week high during trading on Monday . The stock traded as high as $21.96 and last traded at $21.92, with a volume of 132537 shares traded. The stock had previously closed at $18.47.
吉勒聯盟股份有限公司(納斯達克:GNLX — 獲得評級) 股票在星期一交易過程中創下 52 周新高。該股票交易高達 21.96 美元，最後交易價為 21.92 美元，成交量為 132537 股。該股票之前已收盤 18.47 美元。
Wall Street Analysts Forecast Growth
華爾街分析師預測增長
Separately, Benchmark assumed coverage on shares of Genelux in a research report on Wednesday, February 15th. They issued a "speculative buy" rating and a $10.00 target price on the stock.
另外，基準在 2 月 15 日星期三的一份研究報告中承擔對基納盧公司股票的覆蓋率。他們發布了「投機性買入」評級和 10.00 美元的股票目標價。
Genelux Stock Down 4.7 %
日內盧股票下降 4.7%
About Genelux
關於基內盧
(Get Rating)
(取得評分)
Genelux Corporation is a clinical-stage biopharmaceutical company. It focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus.
格內盧公司是一家臨床階段的生物製藥公司。它專注於為患有侵略性和/或難以治療的實體腫瘤類型的患者開發下一代單體免疫療法的管道。該公司最先進的候選產品 Olvi-VEC 是一種專有的，改性的疫苗病毒菌株，一種穩定的 DNA 病毒。
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on Genelux (GNLX)
- Occidental Petroleum: What Would Warren Buffett Do?
- Is Unity Software Earnings Fallout a Buying Opportunity?
- Why Wall Street Is Still So Constructive on Aecom Stock
- Latest Tech Layoffs at Dell May Provide Buying Opportunity
- Here's What Happens When a Stock is Removed from an Index
- 獲取有關基因盧經濟聯盟（GNLX）的研究報告的免費副本
- 西方石油：沃倫·巴菲特會做什麼？
- 是統一軟件盈利輻射購買機會?
- 為什麼華爾街在 Aecom 股票上仍然如此建設性
- Dell 最新技術裁員可能會提供購買機會
- 這是從指數中刪除股票時會發生什麼情況
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
接收基納盧日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Genelux 及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧